POM121L12 inhibitors are a class of chemical compounds that specifically target the protein POM121L12. POM121L12 is one of the many proteins that play a crucial role in the nuclear pore complex (NPC), which regulates the transport of molecules between the nucleus and the cytoplasm in eukaryotic cells. The NPC functions as a gatekeeper, controlling the flow of proteins, RNA, and other macromolecules, ensuring that only the appropriate substances pass through the nuclear envelope at the correct time. POM121L12 is an integral part of this complex structure, involved in the intricate assembly and maintenance of the NPC. The exact mechanism of how POM121L12 operates within the NPC is an area of intense study, but it is known that it contributes to the overall functionality and structural integrity of the pore complex.
Inhibitors targeting POM121L12 are designed to bind to this protein, affecting its normal function. By doing so, these inhibitors can alter the operation of the NPC, which has a cascade of effects within the cellular environment. The exact binding sites and interaction patterns of these inhibitors with POM121L12 are the focus of ongoing research, as understanding these interactions at a molecular level is crucial for the design and development of these compounds. The inhibitors themselves can vary widely in their structure, ranging from small molecules to more complex organic compounds. The specificity of the inhibitors for POM121L12 is a key aspect of their design, as off-target effects can lead to unintended consequences within the cell. Researchers utilize various techniques, such as X-ray crystallography, cryo-electron microscopy, and computational modeling, to elucidate the inhibitors' structures and their interactions with POM121L12, aiming to achieve a high degree of specificity and efficiency in their inhibitory action.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Sirolimus is an mTOR inhibitor that can downregulate protein synthesis by inhibiting the mTORC1 complex, which could lead to decreased levels of POM121L12 if it is regulated by mTOR signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor, which can disrupt the PI3K/AKT/mTOR pathway, indirectly leading to reduced synthesis of POM121L12 if it is downstream of this signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, which, like Wortmannin, can affect the PI3K/AKT/mTOR pathway, potentially decreasing the expression or activity of POM121L12. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that impedes the MAPK/ERK pathway, which might regulate the transcription or translation of POM121L12 through its downstream effects. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could influence the stress-activated MAPK pathway, potentially affecting the expression or stability of POM121L12. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which could disrupt signaling pathways that might regulate the expression or function of POM121L12. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which impedes the MAPK/ERK pathway and could have an impact on POM121L12 expression if it's involved in this signaling route. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is an ATP-competitive inhibitor of mTOR that affects both mTORC1 and mTORC2 complexes, potentially decreasing the expression or activity of POM121L12 through these pathways. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor that can arrest the cell cycle, which might lead to reduced expression of POM121L12 if its levels are associated with the cell cycle. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor which could decrease the stability of POM121L12 by preventing its degradation, leading to a net decrease in its functional activity. | ||||||